Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 14/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 13/20 | 0.48 |
| ▸ | CASP7 | P55210 | 13/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 13/20 | 0.48 |
| ▸ | HPGD | P15428 | 8/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15263344 | 0.84 | ALDH1A1 (0.41) | ALDH1A1CASP1CYP1A2CASP7HSD17B10 | |
| SCHEMBL30313619 | 0.80 | PIK3CA (0.52) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL11078075 | 0.78 | KDM4E (0.54) | ALDH1A1KDM4EADRB1TAAR1 | |
| SCHEMBL10721643 | 0.78 | ALDH1A1 (0.54) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL10869896 | 0.76 | ALDH1A1 (0.37) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL2508000 | 0.72 | SCD (0.49) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL10502433 | 0.72 | ALDH1A1 (0.47) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL7311364 | 0.72 | ALDH1A1 (0.47) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL7269241 | 0.71 | ROCK2 (0.50) | ALDH1A1KDM4ECASP1CYP1A2CASP7 | |
| SCHEMBL795485 | 0.71 | ALDH1A1 (0.46) | ALDH1A1KDM4ECASP1CYP1A2CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0134922-B1 | 2-PIPERAZINO-PTERIDINES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1988-12-14 | — | — | EP | claimed |
| EP-0134922-A1 | 2-Piperazino-pteridines, processes for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-03-27 | — | — | EP | claimed |
| US-8877756-B2 | Substituted pteridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| EP-2032585-B1 | SUBSTITUTED PTERIDINES AS THERAPEUTIC AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2029600-B1 | SUBSTITUTED PTERIDINES SUBSTITUTED WITH A FOUR-MEMBERED HETEROCYCLE | BOEHRINGER INGELHEIM INT (DE) | 2012-03-14 | — | — | EP | disclosed |
| EP-1819708-B1 | SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100234347-A1 | Substituted Pteridines substituted with a Four-Membered Heterocycle | BOEHRINGER INGELHEIM INTERNATIONL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-7750009-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-7718654-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20100120766-A1 | Substituted Pteridines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-7674788-B2 | 7-amino-6-chloro-2-piperazin-1-yl-4-pyrrolidin-1-yl-pteridine; central nervous system, respiratory, gastrointestinal or inflammatory diseases; joints, skin or eyes diseases; cancer; phosphodiesterase 4 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| WO-2003062240-A1 | PTERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-07-31 | — | — | WO | disclosed |
| EP-0134922-B1 | 2-PIPERAZINO-PTERIDINES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1988-12-14 | — | — | EP | disclosed |
| EP-0134922-B1 | 2-PIPERAZINO-PTERIDINES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1988-12-14 | — | — | EP | disclosed |
| EP-0185259-A2 | Pteridines, process for their preparation, and their use as intermediates or as medicaments | Dr. Karl Thomae GmbH (DE) | 1986-06-25 | — | — | EP | disclosed |
| US-4560685-A | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-12-24 | — | — | US | disclosed |
| US-4560685-A | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-12-24 | — | — | US | disclosed |
| EP-0134922-A1 | 2-Piperazino-pteridines, processes for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0134922-A1 | 2-Piperazino-pteridines, processes for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-03-27 | — | — | EP | disclosed |
| EP-0134922-A1 | 2-Piperazino-pteridines, processes for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120766-A1 | Substituted Pteridines | PMP22, TLR5, NQO1 | ALDH1A1 1539/4885KDM4E 2785/4885CASP1 2406/4885 |
| US-20100234347-A1 | Substituted Pteridines substituted with a Four-Membered Heterocycle | UACA, LTC4S, PMP22 | ALDH1A1 894/4885KDM4E 3502/4885CASP1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.